A European study finds hospitalisations and insufficient growth reduce health-related quality of life in childhood ...

Use of race-based reference equations in pulmonary function testing has led to thresholds for what qualifies as impairment in populations.

Regulatory officials have granted Molbreevi priority review and assigned a goal date of Aug. 22, 2026. If approved, Molbreevi will be priced between $400,000 and $500,000 per year.

For most Americans, the letters "NTM" don’t mean anything. But for tens of thousands of people across the country, they represent something serious: a chronic lung disease that’s often overlooked, ...

Malaysia has a new national plan to tackle cancer, tuberculosis, and chronic respiratory conditions in a single approach. Jacqui Thornton reports.

Gossamer Bio's drug for pulmonary arterial hypertension failed to achieve the primary endpoint of a Phase 3 clinical trial.

DOCTOR, WHEN YOU GET SICK, WOMEN ARE MORE LIKELY TO EXPERIENCE CERTAIN LUNG RELATED SYMPTOMS THAN MEN. JOINING US THIS MORNING WITH MORE IS MERCY MEDICAL CENTER PULMONOLOGIST DOCTOR ANTHONY ROWE. GOOD ...

Proton pump inhibitor (PPI) use in patients with chronic obstructive airway diseases is associated with an increased exacerbation risk.

Feb 23 (Reuters) - Gossamer Bio said on Monday its experimental drug for patients with a type of lung condition missed the main goal of a late-stage study, sending the drug developer's shares down 80% ...

You have a chance to take on the challenge and help support Iowans battling lung disease in the Fight for Air Climb. Heather ...